Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01511822|
Recruitment Status : Completed
First Posted : January 19, 2012
Last Update Posted : January 19, 2012
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome with a variety of metabolic and endocrine abnormalities and clinical symptoms.
The primary defect in PCOS consists of an abnormal androgen synthesis and secretion, particularly by ovarian theca cells. Insulin resistance and obesity may act as triggers, explaining the frequent association of PCOS with these metabolic conditions. Hyperinsulinaemia, which results from insulin resistance, stimulates both ovarian and adrenal androgen secretion and suppresses sex hormone-binding globulin synthesis from the liver. It results in an increase in free, biologically active androgens which are related to clinical signs such as hirsutism, acne, seborrhea, and alopecia.
Combined oral contraceptive (COC) therapy is a common treatment for PCOS and it was widely used in this group of patients providing clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain.
More recent studies outlined a deficiency in myo-inositol in women with PCOS and insulin-resistance. Myo-inositol is a precursor for many inositol-containing compounds and it plays critical and diverse roles in signal transduction, membrane biogenesis, vesicle trafficking, and chromatin remodeling. It is a precursor in the synthesis of phosphatidylinositol polyphosphates (PIPs) that are a source of several second messengers.
It has been reported that the administration of myo-inositol reduces serum insulin, decreases serum testosterone and enhances ovulation.
Due to the different beneficial actions, the aim of the present study is to evaluate the clinical, metabolic and endocrine effects of treatment with COC (drospirenone and ethinyl estradiol)alone or in combination with myo-inositol, in young women with PCOS and insulin resistance.
|Condition or disease||Intervention/treatment||Phase|
|PCOS Polycystic Ovary Syndrome||Drug: Drospirenone Ethinyl estradiol Drug: Drospirenone Ethinyl estradiol Myo-inositol Drug: placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Active Comparator: Drospirenone + Ethinyl estradiol||
Drug: Drospirenone Ethinyl estradiol
Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
|Experimental: Drospirenone + Ethinyl estradiol + Myo-inositol||
Drug: Drospirenone Ethinyl estradiol Myo-inositol
Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
|Placebo Comparator: Placebo||
- Score acne (acne grading system by Cook et al)
- Score hirsutism (Ferriman-Gallwey classification)
- Measurement of sex hormones in serum
- Oral glucose tolerance test (OGTT)
- Measurement of blood glucose and insulin levels
- Number of patients with adverse effects
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01511822
|Istituto di Patologia Ostetrica e Ginecologica|